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Objective: The objective of this study was to apply the newly standardized definition for 
sarcopenia from the Foundation for the National Institutes of Health (FNIH) and the current 
definition for obesity to 1) determine the prevalence of sarcopenic obesity (SO) in obese elderly 
women; 2) compare the muscle strength, lean body mass, and markers of inflammation between 
obese elderly women with SO and nonsarcopenic obesity (NSO), and 3) elucidate the relation-
ship between appendicular lean mass adjusted for body mass index (aLM/BMI) with muscle 
strength, lean body mass, and obesity indices. 
Methods: A total of 64 elderly obese women (age: 68.35±6.04 years) underwent body composi-
tion analysis by dual-energy X-ray absorptiometry. Participants were classified into two groups 
according to the definition of SO and NSO. Blood samples were collected for total cholesterol, 
triglycerides, high-density lipoprotein, low-density lipoprotein, uric acid, urea, interleukin-6 
(IL-6), glucose, and creatine kinase (CK) measurements. 
Results: The SO group presented a significantly greater BMI, fat (%), glucose, a marginal 
trend toward significance for uric acid, and IL-6 compared to the NSO group. In addition, the 
SO group displayed lower values for muscle strength and lean body mass. From a correlation 
standpoint, a higher aLM/BMI was positively associated with lean body mass and muscle 
strength and negatively associated with a lower BMI and percentage body fat. 
Conclusion: The definition criteria from FNIH and obesity permit the ability to illustrate the 
prevalence and identify SO in elderly women with low muscle mass, low muscle strength, and 
impaired markers of inflammation.
Keywords: aging, fat mass, muscles, obesity, sarcopenia, sarcopenic obese
Introduction
During aging, a decline in muscle mass coupled with an increase in fat mass has impor-
tant consequences for older adults.1 Four body composition phenotype characteristics 
exist in older adults: normal, sarcopenic, obese, and a combination of sarcopenic and 
obese.2 Although the definition of sarcopenic obesity (SO) combines those of sarcopenia 
and obesity, few diagnostic methods have been proposed in recent years.2–4
Obesity can be diagnosed by total fat mass, percentage body fat, body mass index 
(BMI), visceral fat area, and waist circumference, while sarcopenia can be diagnosed 
by appendicular lean mass adjusted for height squared (aLM/height2 or BMI [aLM/
BMI]).6 The aLM/height2 method has been widely used in many studies, while the 
aLM/BMI method represents a new clinically relevant criteria for weakness and low 
muscle mass based on a large, diverse, and well characterized set of populations of 
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community-dwelling elderly persons that permit generaliz-
ability of findings.1,5–9
The combination of sarcopenia and obesity has a detri-
mental impact on physical functional status in obese elderly 
women, which in turn exacerbates disability.2,10 SO is also 
associated with systemic inflammation (eg, higher C-reactive 
protein, fibrinogen, interleukin-6 [IL-6]), lower handgrip 
strength, lower lean body mass, higher mortality risk, lower 
muscle quality caused by fat infiltration, impaired quality of 
life, higher cardiovascular disease risk, and more physical 
disabilities when compared with subjects without SO.3,8,11–16
Considering that SO research is in its infancy and differ-
ent mathematical thresholds can over- and under-diagnose 
this clinical condition, our goal was to 1) apply the newly 
standardized definition for SO used in previous studies and 
proposed by the Foundation for the National Institutes of 
Health (FNIH) and illustrate the prevalence of SO in obese 
elderly women; 2) observe the degree of impairment of 
muscle strength, lean body mass, and markers of inflam-
mation in those fulfilling such criteria; and 3) elucidate the 
association between aLM/BMI with obesity indices and 
strength parameters.6,8,9,11,17
We hypothesized that obese elderly women with SO will 
have higher pro-inflammatory markers when compared to 
NSO elderly women. Furthermore, we hypothesized that 
a higher aLM/BMI will be positively associated with lean 
body mass and muscle strength and negatively associated 
with obesity indices.
Materials and methods
Ninety elderly women from a local community were 
recruited through posters and lectures about the study at 
the Federal District, Brazil. To be eligible, women needed 
to be aged ≥60 years with a body fat percentage ≥38% as 
assessed by dual-energy X-ray absorptiometry (DXA).11,17 
Exclusion criteria included history of heart failure, valvular 
or congenital disease, pacemaker implantation, or osteo-
articular disorders. A total of 90 older women were assessed 
for eligibility and completed a self-report questionnaire that 
accounted for cardiovascular disease, hypertension, diabetes, 
osteoporosis, or musculoskeletal conditions that may have 
precluded participants from safely completing physical 
function tests assessed in this study. Elderly women were 
classified as hypertensive and with type 2 diabetes mel-
litus by the diagnostic criteria used in previous studies.18–20 
From the initial applicants, 26 were excluded (did not meet 
inclusion criteria) and thus a total of 64 women who met the 
inclusion criteria were selected to participate. The present 
study was approved by the Institutional Research Ethic Com-
mittee of Catholic University of Brasília (UCB) (protocol 
#035/2011). The study design and employed procedures 
were in accordance with ethical standards and the Declara-
tion of Helsinki. Each participant was fully informed about 
the risks associated with study participation and gave their 
written informed consent.
Muscle strength evaluation
Muscle strength was evaluated by the ten-repetition maxi-
mum (10 RM) test according to the protocol used in previous 
research from our laboratory.21,22 The test-retest reproduc-
ibility for the leg extension 10 RM was R=0.99. In addition, 
the relative muscle strength was calculated by dividing the 10 
RM test value by body mass.23 In addition, the leg extension 
exercise was chosen because lower limb strength has a strong 
correlation with elderly survival time and dependency.24
Blood samples and biochemical 
parameters
Lipid profile glycerol phosphate dehydrogenase/p-chloro-
phenol in presence of peroxidase, urea (Ureasi-glutamate 
dehydrogenase), and uric acid (uricase/peroxidase method) 
were measured by the enzymatic colorimetric method using 
Autohumalyzer equipment (Human GMBH, Wiesbaden, 
Germany). High-density lipoprotein cholesterol was deter-
mined by ionic exchange followed by colorimetric reaction 
with the Linco Research Inc. kit (St Louis, MO, USA), and 
blood glucose was measured by the hexokinase enzymatic 
assay. IL-6 concentration was measured by Quantikine high-
sensitivity commercial enzyme-linked immunosorbent assay 
kit (R&D Systems, Minneapolis, MN, USA). The intraassay 
coefficient of variation of the kit was 1.5%–5.6% for IL-6. 
The inter-assay coefficient of variation was 4.3%–6.4% for 
IL-6. Creatine kinase (CK) concentration was determined by 
using a commercially available Reflotron CK assay using the 
Reflotron system (Boehringer Mannheim GmbH, Mannheim, 
Germany). The measures for CK and IL-6 were performed 
in triplicate and then averaged.
Body composition
Body composition procedures have been described in detail 
elsewhere, and percent body fat and appendicular skeletal 
muscle mass were determined via DXA (General Electric-GE 
model 8548 BX1L, year 2005, Lunar DPX type, Software 
Encore 2005; Rommelsdorf, Germany). The coefficient of 
variation for the percent body fat estimated by DXA was 
10.12% and 12.13% for the SO and nonsarcopenic obesity 
(NSO) groups, respectively. All metal objects were removed 
from the participants before the scan.25
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sarcopenia and sO
Prevalence of sarcopenia was defined by the aLM adjusted 
for BMI <0.512.6,8 Obesity was considered as a body fat 
percentage ≥38%. SO was determined if elderly women 
fulfilled the criteria for both sarcopenia and obesity using 
these definitions.4–6,11,17
statistical analysis
All analyses were conducted with SPSS software version 
18.0 (SPSS Inc., Chicago, IL, USA) and the normality 
was verified by the Shapiro–Wilk test. For the parametric 
and non-parametric data, an independent Student’s t-test 
and Mann–Whitney U test were employed, respectively. In 
addition, the Spearman’s rank correlation coefficient was 
used to test the association of aLM/BMI with biochemical 
parameters, muscle strength, and body composition. A chi-
squared test for proportions (Fisher’s exact test when cells 
with expected values were <5 for essential hypertension and 
type 2diabetes mellitus) was also employed. An alpha level 
of P≤0.05 was considered significant. In addition, GraphPad 
Prism 7.0 software was also used (GraphPad Software, Inc., 
La Jolla, CA, USA). An effect size d of 2.31, a power >80%, 
alpha error probability of 0.05, allocation ratio of 1.06, and 
two tails were considered. The post hoc power analysis was 
used to calculate the sample size necessary to identify dif-
ferences between two independent groups. Sixty-two elderly 
(31 vs 31) women were necessary to identify a difference on 
aLM adjusted for BMI. For the power calculation, the soft-
ware G*Power 3.1.6 was used (Heinrich-Heine-University 
Düsseldorf, Düsseldorf, Germany).
Results
The SO group presented a significantly lower absolute 
muscle strength (35.60±7.88 kg [37.71–38.50 95% CI] vs 
40.30±8.38 kg [37.32–43.27 95% CI]) and relative muscle 
strength (0.51±0.12 kg/kg [0.47–0.56 95% CI] vs 0.60±0.12 
kg/kg [0.56–0.65 95% CI]), arm lean body mass (3.76±0.55 
kg [3.56–3.97 95% CI] vs 4.02±0.60 kg [3.80–4.23 95% CI]), 
leg lean body mass (10.90±1.28 kg [10.43–11.37 95% CI] vs 
11.76±1.22 kg [11.33–12.20 95% CI]), and aLM (14.67±1.58 
kg [14.09–15.25 95% CI] vs 15.79±1.60 kg [15.22–16.36 
95% CI]) compared to the NSO group (Figure 1).
Furthermore, the SO group presented a significantly 
greater BMI, fat (%), glucose, and a marginal trend toward 
significance for uric acid, and IL-6 (4.76±5.46 pg/ml 
[2.76–6.80 95% CI] vs 2.58±3.00 pg/ml [1.51–3.64 95% CI]) 
compared to the NSO group (Table 1; Figure 1). In addition, 
there was a significant positive correlation between aLM/
BMI with relative muscle strength, arm lean body mass, leg 
lean body mass, and aLM. However, there was also a sig-
nificant negative correlation between aLM/BMI with body 
fat percentage (Table 2). Furthermore, a marginal trend was 
observed for a negative correlation with glucose.
There was no statistical difference between groups for 
the presence of hypertension (X²(1) =0.21, P=0.80, Cra-
mer’s V=0.05) and diabetes (X²(1) =0.00, P=1.00, Cramer’s 
V=0.01).
Discussion
Our results highlight the prevalence of SO in a relatively 
small sample of obese elderly women using the newly stan-
dardized FNIH definition of ALM combined with obesity 
based on body composition. In addition, our results indicate 
that elderly women with SO present lower levels of lean 
body mass and muscle strength, higher glucose, and a trend 
toward a statistical significance for a higher uric acid and IL-6 
serum levels as compared with NSO elderly women. Other 
important findings include a positive correlation between 
aLM/BMI with lean body mass and muscle strength, and 
a negative association with BMI and percentage body fat.
Inflammation associated with SO plays an important 
role in insulin resistance, glucose tolerance, reduced lean 
body mass, and lower muscle strength.3,16,26,27 An alternative 
hypothesis for the higher glucose levels observed in the 
SO group is that rather than low levels of lean body mass 
being responsible for glucose intolerance, the condition may 
instead be primarily a function of the higher accumulation 
of visceral fat.28
This might be explained by the superior IL-6 serum levels 
when compared with the NSO group. In addition, chronic 
IL-6 elevations activate the transcription nuclear factor-kB 
and JUN N-terminal kinase pathways associated with insulin 
resistance,27,29 thus promoting a higher level of glucose in the 
SO group compared with NSO group as verified in this study.
Furthermore, higher IL-6 serum levels are observed in 
individuals with obesity and poor muscle strength.16 Consis-
tent with this result, we found a trend for greater IL-6 serum 
levels in the SO group. Moreover, the low muscle strength 
and lean body mass observed in the SO group might be 
explained by the activation of molecular pathways as FOXO, 
Smad 2/3, p38MAPK promoted by IL-6 that causes protein 
degradation by the ubiquitin ligases and thereby negatively 
regulates muscle mass and strength in sarcopenic individu-
als.30 Although no standard for IL-6 serum levels has been 
established for reference in clinical practice, older women 
with high IL-6 serum levels (>3.10 pg/mL) have a higher risk 
of developing physical disabilities (eg, associated with low 
muscle strength) as observed in the present study for the SO 
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group when compared with the NSO group (4.76 vs 2.58 pg/
mL for IL-6, respectively).22,26
On the basis of this finding, SO demonstrated a statisti-
cal trend for higher uric acid when compared to NSO group. 
One possible explanation is that visceral adiposity demon-
strates a higher urinary excretion (eg, overproduction-type 
hyperuricemia).31 In addition, central obesity (aka visceral 
adiposity) is associated with a proinflammatory condition 
and insulin resistance.16,32 Central obesity to a greater extent 
directly affects inflammation, functional impairment, and uric 
acid serum levels.16,31,33 SO group in our study might have 
a central obesity characteristic rather than regional obesity 
when compared with NSO, although not directly verified 
by DXA. Furthermore, uric acid might also induce insulin 
resistance, which could partially explain the higher glucose 
serum levels observed in the SO group.32
SO has been shown to be related to physical limitations, 
impaired basic activities of daily living, and impaired instru-
mental activities of daily living.9 The low muscle strength 
observed in our SO group may increase the likelihood for 
these maladies and lead to premature mortality.12 Thus, main-
taining a higher aLM/BMI is positively associated with lean 
body mass and muscle strength while negatively associated 
with a lower BMI and percent body fat. Furthermore, there 
was a trend toward a negative association with glucose toler-
ance, which may have beneficial health implications.
Our exploratory analysis provides additional insight 
into the relationship between SO, inflammation, low muscle 
strength, glucose intolerance, and uric acid concentrations. 
However, these important findings are highly dependent on the 
specific definitions used for sarcopenia and obesity, which may 
result in over- or under-diagnosis of this clinical condition.6,11,17
Accordingly, our findings would necessarily change when 
a different method is employed.5,7 Although this represents an 
important limitation, our results corroborate the relationship 
between SO and functional disabilities and inflammation where 
using the aLM/BMI method demonstrated stronger strengths of 
associations and clinical applicability.8,9 Our findings are also 
limited by the relatively small sample size that compromises 
statistical power, how well the sample reflected the true underly-
ing population of obese elderly women, and the cross-sectional 
design employed precludes the determination of causality.
Table 1 Participant characteristics presented by mean, SD, and 95% CI 
 SO (N=31) NSO (N=33) P-value
Age (years)* 68.19±5.06 (66.33–70.05) 68.51±6.91 (66.06–70.96) 0.859
Body weight (kg) 70.11±12.82 (65.41–74.82) 66.90±10.42 (63.20–70.59) 0.274
BMI (kg/m²)* 31.19±4.35 (29.60–32.79) 27.76±3.98 (26.34–29.17) 0.002
Height (m) 1.49±0.05 (1.47–1.51) 1.55±0.04 (1.53–1.56) 0.001
Fat (%)* 45.17±4.46 (43.54–46.81) 42.97±3.54 (41.71–44.22) 0.050
Fat (kg)* 30.44±8.71 (27.24–33.63) 28.47±5.75 (26.43–30.51) 0.532
aLM/BMI* 0.43±0.03 (0.46–0.48) 0.57±0.08 (0.54–0.60) 0.001
Total cholesterol (mg/dL) 215±32.45 (203.48–227.71) 209.42± (196.72–222.12) 0.482
Triglycerides (mg/dL)* 155.50±57.94 (133.86–177.13) 145.57±62.09 (123.55–167.59) 0.372
HDL (mg/dL) 47.60±11.69 (43.23–51.96) 46.21±11.35 (42.18–50.24) 0.629
LDL (mg/dL) 137.24±32.27 (125.18–149.29) 134.06±33.10 (134.06–122.32) 0.711
Uric acid (mg/dL) 5.10±1.51 (4.53–5.67) 4.48±1.23 (4.05–4.92) 0.084
Urea (mg/dL) 33.28±7.14 (30.61–35.95) 36.21±8.34 (33.25–39.17) 0.142
CK (U/L)* 94.56±33.82 (81.93–107.19) 104.54±44.00 (88.94–120.14) 0.215
Glucose (mg/dL)* 108.52±39.84 (93.64–123.40) 95.48±21.40 (87.89–103.07) 0.010
Note: *Non-normal data.
Abbreviations: aLM, appendicular lean mass, BMI, body mass index, HDL, high-density lipoprotein, LDL, low-density lipoprotein, CK, creatine kinase, SO, sarcopenic 
obesity, NOS, nonsarcopenic obesity.
Table 2 Correlation coefficient between aLM/BMI and 
biochemical parameters, muscle strength, and body composition
Correlation coefficient
R P-value
IL-6 (pg/mL) –0.18 0.153
Glucose (mg/dL) –0.22 0.080
Uric Acid (mg/dL) –0.15 0.214
Absolute muscle strength (kg) 0.17 0.167
Relative muscle strength (kg) 0.32 0.001
Arms lean body mass (kg) 0.24 0.056
Legs lean body mass (kg) 0.32 0.002
aLM (kg) 0.35 0.004
BMI (kg/m²) –0.53 0.001
Fat (%) –0.39 0.001
Note: P≤0.05, significant difference.
Abbreviations: IL-6, interleukin-6, aLM, appendicular lean mass, BMI, body mass 
index.





In addition, we suggest the need of other strength mea-
sures to be comparable with other studies of sarcopenia and 
the need for future research including more details regard-
ing visceral fat such as waist–hip ratio or separation of fat 
deposits using DXA or other imaging measures.
Conclusion
Our results suggest that SO in elderly women is associated 
with higher IL-6 serum levels, lower muscle strength, lower 
lean body mass, higher glucose, and higher uric acid levels. 
Furthermore, the use of definition criteria from FNIH and 
obesity might permit the identification of elderly women 
with SO and allow researchers in clinical geriatric practice to 
plan possible interventions to reduce the burden of disability 
downstream.6,11,17
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